8.17
+1.62%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Iovance Biotherapeutics
From its filings with the US Securities and Exchange Commission
Iovance Biotherapeutics is based in San Carlos, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker IOVA. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $263.5m and a net loss of $391.0m. At that date it held total assets of $913.2m and shareholders' equity of $698.6m.
We are a commercial-stage biopharmaceutical company pioneering a transformational approach to treating cancer. Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers. TIL cell therapies harness the individual immune system’s ability to recognize and destroy diverse cancer cells that are unique to each patient. These individualized therapies are manufactured using centralized, scalable, and proprietary manufacturing processes which rejuvenate and multiply each patient’s polyclonal T cells into the billions.
Iovance was founded to build upon the promise of TIL cell therapy initially developed at academic research centers, including the National Cancer Institute, or the NCI. Our multi-center trials, scalable manufacturing, regulatory approvals and commercial infrastructure have transformed TIL cell therapy from a research product available to only a small number of patients, into a commercially viable treatment that is accessible for thousands of cancer patients.
Our two commercial products include Amtagvi® (lifileucel) and Proleukin® (aldesleukin), an interleukin-2, or IL-2, product used in the Amtagvi® treatment regimen and other applications.
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Jun 2008
- Employees
- 975
- Website
- iovance.com ↗
- Head office
- 825 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Dr. Iain DukesIndependent Chairman of the Board, since 2016$2.6m
- Dr. Frederick VogtInterim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary$11.0m
- Ms. Corleen RocheChief Financial Officer
- Dr. Igor BilinskyChief Operating Officer$3.2m
- Dr. Friedrich Graf FinckensteinChief Medical Officer$3.3m
- Mr. Daniel KirbyChief Commercial Officer
- Dr. Raj PuriChief Regulatory Officer$3.2m
- Dr. Athena CountouriotisIndependent Director$1.3m
- Mr. Ryan MaynardIndependent Director$1.3m
- Mr. Wayne RothbaumIndependent Director$1.9m
- Dr. Michael WeiserIndependent Director$2.4m
- Ms. Wendy YarnoIndependent Director$902,242
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 31
- Environment
- 15
- Social
- 30
- Governance
- 47
- Women in the workforce
- 54%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong pipeline of innovative immunotherapies.
- Patented technology platform providing a competitive advantage.
- Expertise in Tumor-Infiltrating Lymphocytes (TIL) therapy.
Weaknesses
- Relatively small market share compared to larger biopharmaceutical companies.
- High research and development costs may impact profitability.
- Limited clinical data available for some products.
Opportunities
- Increasing demand for personalized cancer immunotherapies.
- Partnerships and collaborations to enhance product development and market reach.
- Potential expansion into new geographic markets.
Threats
- Intense competition in the immunotherapy industry.
- Stringent regulatory requirements and compliance challenges.
- Economic downturn or changes in reimbursement policies affecting healthcare spending.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.